Bio-AI-Lab is a research-driven company at the forefront of integrating artificial intelligence with biological sciences. Our primary mission is to develop and apply advanced AI and machine learning models to decipher complex biological data, accelerate scientific discovery, and create innovative solutions for pressing healthcare challenges. We focus on areas such as genomics, proteomics, drug target identification, predictive diagnostics, and the development of novel therapeutic strategies. By fostering a multidisciplinary environment, Bio-AI-Lab aims to translate computational insights into tangible advancements in biotechnology and medicine.
Serves as the central nexus for research and development, AI model creation, biological experimentation, data analysis, and corporate administration. It is where our core scientific and technical teams collaborate.
State-of-the-art BSL-2 laboratories, high-performance computing clusters for AI training, advanced microscopy suites, and collaborative open-plan workspaces designed to foster interdisciplinary synergy.
A dynamic, intellectually stimulating, and collaborative environment. We champion curiosity, rigorous scientific inquiry, and ethical innovation. Our culture encourages cross-functional teamwork between AI specialists, computational biologists, and wet-lab scientists, with a strong emphasis on continuous learning and knowledge sharing.
Strategically situated in Cambridge, MA, to leverage the rich ecosystem of academic institutions (like MIT and Harvard), leading biotech companies, research hospitals, and a deep talent pool in both AI and life sciences.
Bio-AI-Lab supports its mission through its main R&D headquarters in Cambridge, MA, and a European collaboration hub in Zurich. Globally, we engage in collaborative research projects with leading academic and industry partners, participate in international scientific conferences, and contribute to global research consortia. Our digital infrastructure allows for secure data sharing and remote collaboration with researchers worldwide, advancing our AI-driven biological discoveries on an international scale.
700 Technology Square (Hypothetical Address)
Cambridge
Massachusetts
USA
Address: Technoparkstrasse 1, 8005 Zürich (Hypothetical)
To foster international research partnerships, access European talent in AI and biotech, and engage with regulatory bodies and research initiatives within the EU and Switzerland.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Bio-AI-Lab' leadership includes:
Bio-AI-Lab has been backed by several prominent investors over the years, including:
Over the last 12 months, Bio-AI-Lab has focused on strengthening its scientific and technological leadership to accelerate its research pipeline. One key leadership appointment was made to enhance our AI research capabilities. The foundational executive team remains stable, driving the company's strategic vision.
Discover the tools Bio-AI-Lab uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
For a company like Bio-AI-Lab, common email formats typically involve the first name, last name, or initials combined with the company domain. Assuming the domain is 'bioailab-hypothetical.com', the most likely formats are [first_initial][last]@[domain] or [first].[last]@[domain].
[first_initial][last]@bioailab-hypothetical.com
Format
athorne@bioailab-hypothetical.com
Example
85%
Success rate
BioIT World (Hypothetical News Outlet) • April 10, 2024
Bio-AI-Lab today announced significant advancements in its AI-driven drug discovery platform, demonstrating a remarkable improvement in predicting drug efficacy for complex diseases. The findings, presented at the Annual Symposium on AI in Medicine, showcase the platform's ability to analyze multi-omics data to identify promising therapeutic candidates faster and more cost-effectively....more
Endpoints News (Hypothetical) • January 22, 2024
Cambridge-based Bio-AI-Lab has successfully closed a $45 million Series B funding round co-led by BioFuture Capital and AI Health Innovators Fund. The company plans to use the capital to scale its AI research teams, expand its computational infrastructure, and advance its discovery programs in oncology and neurodegenerative disorders....more
Nature Machine Intelligence (Hypothetical) • September 05, 2023
A research team from Bio-AI-Lab has published a paper in Nature Machine Intelligence detailing a new deep learning architecture that significantly advances the prediction of complex protein structures and interactions. This breakthrough has implications for understanding disease mechanisms and designing targeted therapies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Bio-AI-Lab, are just a search away.